Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Aug 7:11:1186.
doi: 10.3389/fphar.2020.01186. eCollection 2020.

Enteral Lactoferrin Supplementation for Preventing Sepsis and Necrotizing Enterocolitis in Preterm Infants: A Meta‑Analysis With Trial Sequential Analysis of Randomized Controlled Trials

Ya Gao  1   2 , Liangying Hou  3 , Cuncun Lu  1   2 , Qi Wang  3 , Bei Pan  4 , Quan Wang  5 , Jinhui Tian  1   2 , Long Ge  3   6
Affiliations
Review

Enteral Lactoferrin Supplementation for Preventing Sepsis and Necrotizing Enterocolitis in Preterm Infants: A Meta‑Analysis With Trial Sequential Analysis of Randomized Controlled Trials

Ya Gao et al. Front Pharmacol. .

Abstract

Background: Several clinical trials investigated the effects of enteral lactoferrin supplementation on the prevention of sepsis and necrotizing enterocolitis (NEC) in preterm infants, but the efficacy and safety remain disputed. Therefore, we systematically evaluated the effect of enteral lactoferrin supplementation in preterm infants through a meta‑analysis with trial sequential analysis (TSA).

Methods: We searched six databases to identify randomized controlled trials (RCTs) that evaluated the effects of lactoferrin supplementation compared with placebo or no intervention in preterm infants. RevMan version 5.3 software was used to estimate pooled relative risks (RRs) with the random-effects model. TSA, subgroup analyses, and meta-regression analyses were also performed.

Results: Nine RCTs with 3515 samples were included. With low to moderate quality of evidence, compared with placebo, enteral lactoferrin supplementation did not significantly decrease the incidences of late-onset sepsis (RR = 0.63, 95% CI: 0.38 to 1.02, P = 0.06), NEC stage II or III (RR = 0.68, 95% CI: 0.30 to 1.52, P = 0.35), all-cause mortality (RR = 0.89, 95% CI: 0.51 to 1.57, P = 0.69), bronchopulmonary dysplasia (RR = 1.01, 95% CI: 0.90 to 1.13, P = 0.92), retinopathy of prematurity (RR = 0.80, 95% CI: 0.49 to 1.32, P = 0.38), invasive fungal infection (RR = 0.27, 95% CI: 0.02 to 3.94, P = 0.34), intraventricular hemorrhage (RR = 1.40, 95% CI: 0.39 to 5.08, P = 0.61), and urinary tract infection (RR = 0.35, 95% CI: 0.11 to 1.06, P = 0.06). Subgroup analysis revealed that lactoferrin significantly reduced the incidence of sepsis in infants with a birth weight below 1500 g (RR = 0.43, 95% CI: 0.22 to 0.84, P = 0.01). TSAs of the primary outcomes showed that the evidence is insufficient and further data is required.

Conclusions: Limited evidence suggested that enteral lactoferrin supplementation was associated with a reduction of late-onset sepsis in infants with a birth weight below 1500g, however, did not decrease the incidence of NEC stage II or III, all-cause mortality, and other adverse events in preterm infants. The present evidence was insufficient to inform clinical practice.

Keywords: lactoferrin; meta‑analysis; mortality; necrotizing enterocolitis; preterm infant; sepsis; trial sequential analysis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow Diagram of Study Selection.
Figure 2
Figure 2
Comparison of the incidence of sepsis between enteral lactoferrin supplementation and placebo.
Figure 3
Figure 3
Comparison of the incidence of NEC stage II or III between enteral lactoferrin supplementation and placebo.
Figure 4
Figure 4
Comparison of mortality between enteral lactoferrin supplementation and placebo.
Figure 5
Figure 5
Comparisons of the incidence of (A) bronchopulmonary dysplasia, (B) retinopathy of prematurity, (C) invasive fungal infection, (D) intraventricular hemorrhage, and (E) urinary tract infection between enteral lactoferrin supplementation and placebo.
See this image and copyright information in PMC

References

    1. Akin I. M., Atasay B., Dogu F., Okulu E., Arsan S., Karatas H. D., et al. (2014). Oral lactoferrin to prevent nosocomial sepsis and necrotizing enterocolitis of premature neonates and effect on T-regulatory cells. Am. J. Perinatol. 31, 1111–1120. 10.1055/s-0034-1371704 - DOI - PubMed
    1. Bangalore S., Kumar S., Kjeldsen S. E., Makani H., Grossman E., Wetterslev J., et al. (2011). Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. Lancet Oncol. 12, 65–82. 10.1016/S1470-2045(10)70260-6 - DOI - PubMed
    1. Barrington K. J., Assaad M. A., Janvier A. (2016). The Lacuna Trial: a double-blind randomized controlled pilot trial of lactoferrin supplementation in the very preterm infant. J. Perinatol. 36, 666–669. 10.1038/jp.2016.24 - DOI - PubMed
    1. Bassler D., Stoll B. J., Schmidt B., Asztalos E. V., Roberts R. S., Robertson C. M., et al. (2009). Using a count of neonatal morbidities to predict poor outcome in extremely low birth weight infants: added role of neonatal infection. Pediatrics 123, 313–318. 10.1542/peds.2008-0377 - DOI - PMC - PubMed
    1. Bell M. J., Ternberg J. L., Feigin R. D., Keating J. P., Marshall R., Barton L., et al. (1978). Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging. Ann. Surg. 187, 1–7. 10.1097/00000658-197801000-00001 - DOI - PMC - PubMed